Clinical Trial Update: Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and efficacy of canakinumab for patients with frequent gout flares who are contraindicated, intolerant to, or not responsi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gouty Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2017-06-08